Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22164454 | 1.00 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2CA14KIF11KMT2A | |
| Hydrochloric Acid SCHEMBL6231526 | 1.00 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2CA14KIF11KMT2A | |
| SCHEMBL2493285 | 0.98 | SMN1; SMN2 (0.37) | ALDH1A1SMN1; SMN2CA14KIF11KMT2A | |
| SCHEMBL7782987 | 0.98 | SMN1; SMN2 (0.37) | ALDH1A1SMN1; SMN2CA14KIF11KMT2A | |
| SCHEMBL6250353 | 0.98 | SMN1; SMN2 (0.37) | ALDH1A1SMN1; SMN2CA14KIF11KMT2A | |
| Methyl Alcohol SCHEMBL28098130 | 0.95 | SMN1; SMN2 (0.36) | ALDH1A1SMN1; SMN2CA14KIF11KMT2A | |
| SCHEMBL10633496 | 0.88 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2CA14KIF11 | |
| Hydrochloric Acid SCHEMBL3394169 | 0.82 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2KIF11KMT2ACA1 | |
| Hydrochloric Acid SCHEMBL4678546 | 0.82 | KMT2A (0.36) | ALDH1A1SMN1; SMN2KIF11KMT2ASLC1A1 | |
| Hydrochloric Acid SCHEMBL4678540 | 0.82 | KMT2A (0.36) | ALDH1A1SMN1; SMN2KIF11KMT2ASLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117903078-A | Amide derivative containing 3, 4-dichloro isothiazole, preparation method and application thereof | 南开大学 | 2024-04-19 | — | — | CN | claimed |
| CN-113519506-B | Protein-free and DMSO-free cell cryopreservation liquid, application and preparation method thereof | 依科赛生物科技（太仓）有限公司 | 2021-12-31 | — | — | CN | claimed |
| CN-113519506-A | Protein-free and DMSO-free cell cryopreservation liquid, application and preparation method thereof | 依科赛生物科技（太仓）有限公司 | 2021-10-22 | — | — | CN | claimed |
| EP-4725560-A2 | ANTI-B7H3 ANTIBODIES FOR THE PREPARATION OF ANTIBODY DRUG CONJUGATES (ADCS) OF KSP INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2026-04-15 | — | — | EP | disclosed |
| US-20250099600-A1 | Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-03-27 | — | — | US | disclosed |
| US-12144865-B2 | Antibody drug conjugates with enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-11-19 | — | — | US | disclosed |
| CN-109310781-B | Specific antibody-drug-conjugates (ADC) having a KSP inhibitor and an anti-CD 123-antibody | 拜耳制药股份公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-117903078-A | Amide derivative containing 3, 4-dichloro isothiazole, preparation method and application thereof | 南开大学 | 2024-04-19 | — | — | CN | disclosed |
| CN-114751863-B | Terpastacin derivative, preparation method thereof and application thereof in preparation of hypoxia factor inhibitor | 中国科学院南海海洋研究所 | 2024-01-05 | — | — | CN | disclosed |
| US-20230399411-A1 | SPECIFIC ANTIBODY-DRUG-CONJUGATES (ADCS) WITH KSP INHIBITORS AND ANTI-CD123-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-12-14 | — | — | US | disclosed |
| US-20230338559-A1 | ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-10-26 | — | — | US | disclosed |
| US-20100105686-A1 | PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-04-29 | — | — | US | disclosed |
| EP-2057116-A1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008050167-A1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2008-05-02 | — | — | WO | disclosed |
| US-6927290-B2 | Production of mixed acid anhydride and amide compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-08-09 | — | — | US | disclosed |
| EP-1160236-B1 | Production of mixed acid anhydride and amine compound | SUMITOMO CHEMICAL CO (JP) | 2005-05-25 | — | — | EP | disclosed |
| US-20040210059-A1 | Production of mixed acid anhydride and amide compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-10-21 | — | — | US | disclosed |
| US-6753431-B2 | REACTING A CARBAMATE DERIVATIVE WITH CARBOXYLIC AND HALOFORMIC ACID DERIVATIVES | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2004-06-22 | — | — | US | disclosed |
| US-20020032346-A1 | Production of mixed acid anhydride and amide compound | SUMITOMO CHEMICAL CO., LTD. | 2002-03-14 | — | — | US | disclosed |
| EP-1160236-A2 | Production of mixed acid anhydride and amine compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040210059-A1 | Production of mixed acid anhydride and amide compound | CA2, CA1, CA3 | CA2 1/4885ALDH1A1 543/4885SMN1; SMN2 2886/4885 |
| US-20020032346-A1 | Production of mixed acid anhydride and amide compound | CA2, CA1, CA3 | CA2 1/4885ALDH1A1 543/4885SMN1; SMN2 2886/4885 |
| US-20100105686-A1 | PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, HRH1 | CA2 1541/4885ALDH1A1 2910/4885SMN1; SMN2 4111/4885 |
| US-20230338559-A1 | ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS | VCAM1, FCGR1A, DNPEP | CA2 1608/4885ALDH1A1 138/4885SMN1; SMN2 3632/4885 |
| US-20250099600-A1 | Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates | KIF18B, KIF18A, KIF5B | CA2 3949/4885ALDH1A1 2674/4885SMN1; SMN2 1367/4885 |
| US-12144865-B2 | Antibody drug conjugates with enzymatically cleavable groups | KIFC1, KIF2C, KIF5B | CA2 2915/4885ALDH1A1 779/4885SMN1; SMN2 1430/4885 |
| US-20230399411-A1 | SPECIFIC ANTIBODY-DRUG-CONJUGATES (ADCS) WITH KSP INHIBITORS AND ANTI-CD123-ANTIBODIES | KIF23, SDCBP, KLK13 | CA2 3053/4885ALDH1A1 741/4885SMN1; SMN2 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.